GSK plc
Exdensur
EGPA
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for Exdensur in EGPA are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 12h ago
“Further pivotal readouts expected in 2026: Exdensur for EGPA;”